UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake

Cancer research (Chicago, Ill.), 2018-01, Vol.78 (2), p.516-527

2018

Volltextzugriff (PDF)

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

Oncotarget, 2017-12, Vol.8 (67), p.111026-111040

2017

Volltextzugriff (PDF)

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Cancer epidemiology, biomarkers & prevention, 2012-11, Vol.21 (11), p.1902-1912

2012

Volltextzugriff (PDF)

Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer

International journal of cancer, 2013-01, Vol.132 (2), p.472-484

2013

Volltextzugriff (PDF)

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Journal of Gynecologic Oncology, 2018, 29(6), , pp.1-7

2018

Volltextzugriff (PDF)

Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up

International journal of clinical oncology, 2010-08, Vol.15 (4), p.406-412

2010

Volltextzugriff (PDF)

Prediction, based on resection margins, of long-term outcome of cervical intraepithelial neoplasia 3 treated by Shimodaira-Taniguchi conization

Archives of gynecology and obstetrics, 2012-05, Vol.285 (5), p.1427-1432

2012

Volltextzugriff (PDF)

Recurrent endometrial carcinoma: prognosis for patients with recurrence within 6 to 12 months is worse relative to those relapsing at 12 months or later

American journal of obstetrics and gynecology, 2011-06, Vol.204 (6), p.535.e1-535.e5

2011

Volltextzugriff (PDF)

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP

International journal of oncology, 2017-04, Vol.50 (4), p.1064-1074

2017

Volltextzugriff (PDF)

Mid-second trimester measurement of fetal nasal bone length in the Japanese population

The journal of obstetrics and gynaecology research, 2006-08, Vol.32 (4), p.403-407

2006

Volltextzugriff (PDF)

Pedunculated Sub-Serous Leiomyosarcoma Mimicking Ovarian Cancer: Case Report and Review of Literature

Gynecology & obstetrics (Sunnyvale, Calif.), 2013, Vol.3 (3)

Yokoyama, Takuhei

2013

Volltextzugriff (PDF)

Abstract 264: The cell cycle checkpoint kinase 1/2 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.264-264

2016

Volltextzugriff (PDF)

Abstract 264: The cell cycle checkpoint kinase 12 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.264-264

2016

Volltextzugriff (PDF)

Abstract 4410: LSR promotes ovarian cancer cell growth following the activation of β-oxidation and its antibody inhibits lipid catabolism

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.4410-4410

2017

Volltextzugriff (PDF)

Abstract 5363: Navitoclax (Nav) and BMN 673 yield cytotoxicity with lower doses than used for single agents in high-grade serous ovarian cancer (HGSOC)

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.5363-5363

2015

Volltextzugriff (PDF)

Annexin A4‐conferred platinum resistance is mediated by the copper transporter ATP7A

International journal of cancer, 2014-04, Vol.134 (8), p.1796-1809

2014

Volltextzugriff (PDF)

Significance of venous thromboembolism in women with uterine carcinosarcoma

Gynecologic oncology, 2018-02, Vol.148 (2), p.267-274

2018

Volltextzugriff (PDF)

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma

Annals of surgical oncology, 2018-11, Vol.25 (12), p.3676-3684

2018

Volltextzugriff (PDF)

Abstract 4382: Anti-human LSR monoclonal antibody inhibits tumor growth of ovarian cancer directly

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.4382-4382

2015

Volltextzugriff (PDF)

Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma

Gynecologic oncology, 2017-12, Vol.147 (3), p.565-571

2017

Volltextzugriff (PDF)

Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion

Gynecologic oncology, 2015-02, Vol.136 (2), p.198-204

2015

Volltextzugriff (PDF)

Abstract 4363: Silencing of JAM-A inhibits cell growth through cell cycle arrest in endometrial cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4363-4363

2013

Volltextzugriff (PDF)

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

Cancer chemotherapy and pharmacology, 2011-04, Vol.67 (4), p.829-835

2011

Volltextzugriff (PDF)

Abstract 4057: Functional domain of Annexin A4: which domain is indispensable for chemoresistance to platinum drugs

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4057-4057

2013

Volltextzugriff (PDF)

Abstract 4059: Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.4059-4059

2013

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

ThemaCarcinosarcoma - Pathology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(35)

Sprache

Englisch
(34)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(16)
Female
(15)
Oncology
(15)
Middle Aged
(9)
Tumors
(9)
Biological And Medical Sciences
(7)
Medical Sciences
(7)
Obstetrics & Gynecology
(7)
Retrospective Studies
(7)
Female Genital Diseases
(6)
Gynecology. Andrology. Obstetrics
(6)
Adult
(5)
Endometrial Cancer
(5)
Medicine
(5)
Medicine & Public Health
(5)
Prognosis
(5)
Aged
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer

Biomarkers for Screening, Diagnosis, and Monitoring of Ovarian Cancer

Plasma membrane proteomics identifies bone marrow stromal antigen 2 as a potential therapeutic target in endometrial cancer

Clinical utility of CA-125 in the management of uterine carcinosarcoma

Endometrial carcinoma: better prognosis for asymptomatic recurrences than for symptomatic cases found by routine follow-up

Prediction, based on resection margins, of long-term outcome of cervical intraepithelial neoplasia 3 treated by Shimodaira-Taniguchi conization

Recurrent endometrial carcinoma: prognosis for patients with recurrence within 6 to 12 months is worse relative to those relapsing at 12 months or later

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP

Mid-second trimester measurement of fetal nasal bone length in the Japanese population

Pedunculated Sub-Serous Leiomyosarcoma Mimicking Ovarian Cancer: Case Report and Review of Literature

Abstract 264: The cell cycle checkpoint kinase 1/2 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations

Abstract 264: The cell cycle checkpoint kinase 12 inhibitor, LY2606368 with PARP inhibition results in synergistic cytotoxicity in high-grade serous ovarian cancer (HGSOC) at lower than physiologically administered concentrations

Abstract 4410: LSR promotes ovarian cancer cell growth following the activation of β-oxidation and its antibody inhibits lipid catabolism

Abstract 5363: Navitoclax (Nav) and BMN 673 yield cytotoxicity with lower doses than used for single agents in high-grade serous ovarian cancer (HGSOC)

Annexin A4‐conferred platinum resistance is mediated by the copper transporter ATP7A

Significance of venous thromboembolism in women with uterine carcinosarcoma

Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma

Abstract 4382: Anti-human LSR monoclonal antibody inhibits tumor growth of ovarian cancer directly

Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma

Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion

Abstract 4363: Silencing of JAM-A inhibits cell growth through cell cycle arrest in endometrial cancer

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

Abstract 4057: Functional domain of Annexin A4: which domain is indispensable for chemoresistance to platinum drugs

Abstract 4059: Annexin A4-conferred platinum resistance is mediated by the copper transporter ATP7A

Aktive Filter

Suchergebnisse filtern